Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 26:8:566.
doi: 10.3389/fneur.2017.00566. eCollection 2017.

Efficacy and the Safety of Granulocyte Colony-Stimulating Factor Treatment in Patients with Muscular Dystrophy: A Non-Randomized Clinical Trial

Dorota Sienkiewicz  1 , Wojciech Kułak  1 , Bożena Okurowska-Zawada  1 , Grażyna Paszko-Patej  1 , Janusz Wojtkowski  1 , Karolina Sochoń  1 , Anna Kalinowska  1 , Kamila Okulczyk  1 , Jerzy Sienkiewicz  2 , Edward McEachern  3
Affiliations

Efficacy and the Safety of Granulocyte Colony-Stimulating Factor Treatment in Patients with Muscular Dystrophy: A Non-Randomized Clinical Trial

Dorota Sienkiewicz et al. Front Neurol. .

Abstract

Introduction: The current standard treatment for patients with Duchenne muscular dystrophy (DMD) involves corticosteroids. Granulocyte colony-stimulating factor (G-CSF) induces the proliferation of satellite cells and myoblasts and, in turn, muscle regeneration. Beneficial effects of G-CSF were also described for skeletal muscle disorders.

Aim: We assessed the safety and effects of using G-CSF to promote muscle strength in patients with DMD.

Materials and methods: Inclusion criteria were as follows: patients aged 5-15 years with diagnosed with DMD confirmed by genetic test or biopsy. Fourteen patients were treated with steroids, and their use was not changed in this study. Diagnoses were confirmed by genetic tests: deletions were detected in 11 patients and duplications in 5 patients. Nineteen 5- to 15-year-old patients diagnosed with DMD-9 were in wheelchairs, whereas 10 were mobile and independent-completed an open study. Participants received a clinical examination and performed physiotherapeutic and laboratory tests to gage their manual muscle strength, their isometric force using a hand dynamometer, and aerobic capacity [i.e., 6-min walk test (6MWT)] before and after therapy. Each participant received G-CSF (5 µg/kg/body/day) subcutaneously for five consecutive days during the 1st, 2nd, 3rd, 6th, and 12th month. Laboratory investigations that included full blood count and biochemistry were performed. Side effects of G-CSF treatment were assessed during each visit. During each cycle of G-CSF administration in the hospital, rehabilitation was also applied. All patients received regular ambulatory rehabilitation.

Results: The subcutaneous administration of G-CSF improved muscle strength in participants. We recorded a significant increase in the distance covered in the 6MWT, either on foot or in a wheelchair, increased muscle force in isometric force, and a statistically significant decrease in the activity of the muscle enzyme creatine kinase after nearly every cycle of treatment. We observed no side effects of treatment with G-CSF.

Conclusion: Our findings suggest that G-CSF increases muscle strength in patients with DMD, who demonstrated that G-CSF therapy is safe and easily tolerable.

Keywords: children; efficacy; granulocyte colony-stimulating factor; muscle strength; muscular dystrophy; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flowchart of granulocyte colony-stimulating factor treatment 1-year therapy of patients with muscular dystrophy. Screening, enrollment, and follow-up.
Figure 2
Figure 2
The treatment protocol schema.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol (2006) 7(10):762–73.10.1038/nrm2024 - DOI - PubMed
    1. Manzur AY, Muntoni F. Diagnosis and treatment in muscular dystrophies. J Neurol Neurosurg Psychiatry (2009) 80:706–14.10.1136/jnnp.2008.158329 - DOI - PubMed
    1. Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry (2013) 84:698–705.10.1136/jnnp-2012-303902 - DOI - PubMed
    1. Mendel JR, Llyod-Puryear M. Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve (2013) 48(1):21–6.10.1002/mus.23810 - DOI - PubMed
    1. Ervasti M, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol (2008) 265:191–225.10.1016/S0074-7696(07)65005-0 - DOI - PubMed

LinkOut - more resources